Replies to post #10246 on FDA Plays

[hondaboost]

YG, that sounds a good plan for SPEX.

But, for me, I'll add more IF it dips to $0.8, instead of 'stop order'.

Lots of exciting events coming:

1. SPEX, revolutionary diabetes drugs:
a. safe
b. Cheap
c. Easily accessible

2. Phase 3 trials done and filing for FDA approval in 6 months;

3. Partnerships in talks currently;

4. Millions of Diabetes patent will be benifited;

5. Multi Billions $ revenue possible;

S/O, just 21 m, while insiders and funds are holding 30-40%.

Short-term target: $2.5-$3;
Long-term target: $5-$7 if it gets FDA's nod.